123 completed, 30 terminated, 23 unknown, 19 recruiting. 223 Phase 3, 35 Phase 2.
Follow Colitis, Ulcerative: new trials by email Literature Review of Colitis, Ulcerative trials Research Report on Colitis, Ulcerative
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nitazoxanide as Adjunct Therapy in Mild-to-Moderate Ulcerative Colitis Nitazoxanide (NTZ) - Ulcerative Colitis (UC) | Phase 2 / Phase 3 | Recruiting | Tanta University | 44 | 2026-10-25 | 2026-11-09 |
| Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis Ponesimod, Placebo - Ulcerative Colitis (UC) | Phase 3 | Recruiting | Vanda Pharmaceuticals | 150 | 2026-09-01 | 2026-08-18 |
| Modafinil for Debilitating Fatigue in Quiescent Inflammatory Bowel Disease MODIFI-IBD Trial) Modafinil, Placebo - Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Chronic Fatigue | Phase 2 / Phase 3 | Recruiting | Radboud University Medical Center | 60 | 2026-08-03 | 2026-09-14 |
| Hemay005 for the Treatment of Chinese Moderately to Severely Active Ulcerative Colitis Hemay005 tablet, Placebo - Ulcerative Colitis (UC) | Phase 3 | Not yet recruiting | Ganzhou Hemay Pharmaceutical Co., Ltd | 360 | 2026-06-01 | 2026-06-16 |
| A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis JNJ-78934804, Guselkumab - Colitis, Ulcerative | Phase 3 | Recruiting | Janssen Research & Development, LLC | 644 | 2026-05-23 | 2026-11-03 |
| A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis Duvakitug, Placebo - Ulcerative Colitis | Phase 3 | Recruiting | Sanofi | 751 | 2026-01-16 | 2026-10-16 |
| A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD) Vedolizumab SC, No Intervention - Ulcerative Colitis, Crohn's Disease | Phase 3 | Recruiting | Takeda | 70 | 2025-10-27 | 2026-10-09 |
| Risankizumab for Fibrostenotic Crohn's Disease Treatment Ustekinumab, Risankizumab - Crohn Disease, Crohn Disease and Ulcerative Colitis | Phase 3 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 260 | 2025-10-20 | 2025-09-16 |
| An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis Duvakitug, Placebo - Ulcerative Colitis | Phase 3 | Recruiting | Sanofi | 980 | 2025-10-08 | 2026-10-23 |
| A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis Icotrokinra, Placebo - Colitis, Ulcerative | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 896 | 2025-10-01 | 2026-11-03 |
| A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis Filgotinib - Ulcerative Colitis | Phase 3 | Recruiting | Alfasigma S.p.A. | 80 | 2025-09-29 | 2026-10-20 |
| A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis Mesalamine, Placebo - Ulcerative Colitis (UC) | Phase 3 | Withdrawn | AbbVie | 2025-09-15 | 2025-08-12 | |
| A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis Risankizumab - Ulcerative Colitis | Phase 3 | Recruiting | AbbVie | 120 | 2025-07-28 | 2026-10-27 |
| Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study Mirikizumab, Tirzepatide, Placebo - Ulcerative Colitis, Obesity or Overweight | Phase 3 | Recruiting | Eli Lilly and Company | 350 | 2025-06-26 | 2026-11-04 |
| A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab Risankizumab, Vedolizumab - Ulcerative Colitis | Phase 3 | Active not recruiting | AbbVie | 573 | 2025-06-17 | 2026-08-04 |
| Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis Upadacitinib Oral Product - Colitis, Ulcerative | Phase 3 | Recruiting | McMaster University | 134 | 2025-04-16 | 2025-06-22 |
| A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease Vedolizumab IV, Vedolizumab SC - Ulcerative Colitis, Crohn's Disease | Phase 3 | Recruiting | Takeda | 70 | 2025-01-22 | 2026-08-03 |
| Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011) Tulisokibart, Placebo to tulisokibart - Crohn Disease, Colitis, Ulcerative | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1380 | 2024-11-25 | 2026-11-03 |
| A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants Guselkumab - Crohns Disease, Colitis, Ulcerative | Phase 3 | Recruiting | Janssen Research & Development, LLC | 196 | 2024-10-29 | 2026-11-03 |
| Vedolizumab in Pediatric Ulcerative Colitis- Comparison With Infliximab Infliximab - Ulcerative Colitis | Phase 3 | Not yet recruiting | JAROSLAW KIERKUS | 60 | 2024-10-01 | 2024-09-26 |
Showing 20 of 223. Sign in to see all of them.
Inflammatory Bowel Diseases (41) · Crohn Disease (27) · Colitis (13) · Gastrointestinal Diseases (7) · Ulcer (7) · Colonic Diseases (5) · Digestive System Diseases (5) · Gastroenteritis (5) · Intestinal Diseases (5) · Anemia (4) · Anemia, Iron-Deficiency (4) · Iron Deficiencies (4) · Pathologic Processes (4) · Proctitis (3)
Colonic Diseases (218) · Digestive System Diseases (218) · Gastroenteritis (218) · Intestinal Diseases (218) · Gastrointestinal Diseases (216) · Colitis (210) · Inflammatory Bowel Diseases (182) · Pathological Conditions, Signs and Symptoms (18) · Pathologic Processes (10) · Hemic and Lymphatic Diseases (6) · Behavior (5) · Disease Attributes (5) · Nutritional and Metabolic Diseases (5) · Anemia, Hypochromic (4) · Health Behavior (4)
Mesalamine (35) · vedolizumab (15) · Adalimumab (13) · Infliximab (10) · mirikizumab (8) · Fecal Microbiota Transplantation (7) · Budesonide (6) · etrolizumab (6) · golimumab (5) · ozanimod (5) · risankizumab (5) · tofacitinib (5) · GLPG0634 (4) · etrasimod (4) · guselkumab (4)
Bausch Health Americas, Inc. (14) · Janssen Research & Development, LLC (13) · AbbVie (12) · Takeda (10) · Shire (9) · Eli Lilly and Company (8) · Ferring Pharmaceuticals (7) · Pfizer (7) · Hoffmann-La Roche (6) · Warner Chilcott (6) · Dr. Falk Pharma GmbH (5) · Facet Biotech (4) · Merck Sharp & Dohme LLC (4) · AbbVie (prior sponsor, Abbott) (3) · Abivax S.A. (3)
United States (128) · Poland (91) · Canada (83) · Germany (82) · Belgium (80) · Hungary (73) · France (71) · Israel (71) · Italy (71) · United Kingdom (69) · Czechia (66) · Japan (63) · Netherlands (61) · Spain (61) · Australia (60)
Bruce Sands, MD, PhD (3) · Severine Vermeire, MD, PhD (3)
PMID 32445184, PMID 29850873, PMID 30476584, PMID 31077827, PMID 31599001, PMID 32766762, PMID 32816215, PMID 32870265, PMID 33324993, PMID 33684552, PMID 34614208, PMID 35648151, PMID 35792493, PMID 36124702, PMID 36336750, PMID 36342120, PMID 36526796, PMID 36931693, PMID 37402275, PMID 37560161, PMID 38425446, PMID 40013523, PMID 26563167, PMID 28467869, PMID 29028981, PMID 29380251, PMID 29743836, PMID 31982148, PMID 33127596, PMID 33513294, PMID 34035832, PMID 34165201, PMID 35380664, PMID 35380740, PMID 35934286, PMID 36271912, PMID 36506749, PMID 38778549, PMID 39448057, PMID 39778975, PMID 42248437, PMID 16339095, PMID 17324131, PMID 17476675, PMID 19596014, PMID 21255059, PMID 21385195, PMID 22617015, PMID 24067881, PMID 25173754
2023 (16), 2017 (10), 2015 (8), 2016 (6), 2018 (6), 2004 (5), 2019 (4), 2025 (3), 2008 (2), 2014 (2), 2009 (1), R01HD099344 (1)